Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

NCT03679624 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT03679624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03679624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 2
Overall status
Terminated
Start date
July 30, 2020
Completion date
October 13, 2020
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia, waldenstrom's disease, waldenstrom's macroglobulinaemia, without mention of remission, waldenstrom's macroglobulinemia of lymph nodes, waldenstrom's macroglobulinemia recurrent, waldenstrom's macroglobulinemia refractory, waldenström; hypergammaglobulinemia